title: Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.
abstract: Growth factor-induced activation of protein kinase-B (PKB), also known as AKT, induces pro-survival signaling and inhibits activation of pro-apoptotic signaling molecules including the Forkhead box O-3a (FOXO3a) transcription factor and caspase in transformed prostate cells in vitro. Earlier we reported that Withaferin-A (WA), a small herbal molecule, induces pro-apoptotic response-4 (Par-4) mediated apoptosis in castration-resistant prostate cancer (CRPC) cells. In the present study, we demonstrate that inhibition of AKT facilitates nuclear shuttling of FOXO3a where it regulates Par-4 transcription in CRPC cells. FOXO3a is upstream of Par-4 signaling, which is required for induction of apoptosis in CRPC cells. Promoter bashing studies and Ch-IP analysis confirm a direct interaction of FOXO3a and Par-4; a sequential deletion of FOXO3a-binding sites in the Par-4 promoter fails to induce Par-4 activation. To confirm these observations, we either overexpressed AKT or silenced FOXO3a activation in CRPC cells. Both methods inhibit Par-4 function and apoptosis is significantly compromised. In xenograft tumors derived from AKT-overexpressed CRPC cells, FOXO3a and Par-4 expression is downregulated, leading to aggressive tumor growth. Oral administration of WA to mice with xenograft tumors restores FOXO3a-mediated Par-4 functions and results in inhibited tumor growth. Finally, an inverse correlation of nuclear localization of AKT expression corresponds to cytoplasmic Par-4 localization in human prostate tissue array. Our studies suggest that Par-4 is one of the key transcriptional targets of FOXO3a, and Par-4 activation is required for induction of apoptosis in CRPC cells. Activation of FOXO3a appears to be an attractive target for the treatment of CRPC and molecules such as WA can be explored further for the treatment of CRPC.
authors.affiliation: Department of Urology, University of Louisville, Louisville, KY 40202, USA.
authors.forename: T P
authors.initials: TP
authors.lastname: Das
authors.affiliation: Department of Urology, University of Louisville, Louisville, KY 40202, USA.
authors.forename: S
authors.initials: S
authors.lastname: Suman
authors.affiliation: Department of Pathology, University of Louisville, Louisville, KY 40202, USA.
authors.forename: H
authors.initials: H
authors.lastname: Alatassi
authors.affiliation: Department of Urology, University of Louisville, Louisville, KY 40202, USA.
authors.forename: M K
authors.initials: MK
authors.lastname: Ankem
authors.affiliation: Department of Urology, University of Louisville, Louisville, KY 40202, USA.
authors.forename: C
authors.initials: C
authors.lastname: Damodaran
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D051017:Apoptosis Regulatory Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D001665:Binding Sites; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D000071316:Forkhead Box Protein O3 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011401:Promoter Regions, Genetic; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism*; D034622:RNA Interference; D011944:Receptors, Androgen / Q000172:deficiency / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects; D054358:Withanolides / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; C499517:FOXO3 protein, human; D000071316:Forkhead Box Protein O3; D011944:Receptors, Androgen; D054358:Withanolides; C101296:prostate apoptosis response-4 protein; D051057:Proto-Oncogene Proteins c-akt; C009684:withaferin A